Thanks, everyone. Welcome to the 43rd Annual JP Morgan Healthcare Conference. My name is Anupam Rama. I'm one of the Senior Biotech Analysts here at JP Morgan. I'm joined by my squad: Priyanka Grover, Malcolm Kuno, and Rathi Pinghe. Our next presenting company is SpringWorks, and presenting on behalf of the company we have CEO Saqib Islam. Saqib. Thank you, Anupam. It's a pleasure to be here once again, and as always, we appreciate the opportunity to present at your conference. Before I start, I'll remind everybody that today's presentation has some forward-looking statements that are subject to a number of risks and uncertainties, an explanation of which are on this slide. Please read it carefully and check out our SEC filings, which are available on our website. So, at SpringWorks, we develop and commercialize life-changing medicines for patients suffering from devastating diseases. Our first medicine, OGSIVEO, is the first and only FDA-approved treatment for desmoid tumors, and we're proud that it has rapidly become already the systemic standard of care for adults with these rare and debilitating tumors. We're still in the early stages, we believe, of realizing the full potential of our opportunity to serve the desmoid tumor community, and we're focused on bringing the transformative benefits of OGSIVEO to a large and growing number of patients. Our second medicine, mirdametinib, is a potentially best-in-class treatment for patients with neurofibromatosis type 1 associated plexiform neurofibromas, or NF1-PN. Our NDA is under priority review, and our PDUFA date is set for February 28th of this year. We are excited for the opportunity to bring this differentiated therapy to both adults and children with NF1-PN in the United States in February and then later on in the year in Europe. In parallel, we are planning to launch both mirdametinib and OGSIVEO in Europe this year. Beyond our work on these two patient groups, we're advancing a diversified portfolio of clinical and preclinical oncology programs and indications with high unmet need, which I'll be speaking about over the course of our presentation. Importantly, we also have durable IP protection for both OGSIVEO and mirdametinib with our suite of issued U.S. patents providing protection into 2043 for both of these important medicines. All of these efforts are supported by our strong financial position, with a balance sheet that we expect to fund us through profitability in the first half of 2026. 2025 is set up to be a very exciting year for us. We are on the cusp of delivering two potentially best-in-class medicines for two distinct patient communities. With OGSIVEO, we're gratified that real-world experience from patients and prescribers shows that lives are being transformed. Patients are benefiting from significant reductions in tumor size and relief of their symptoms, including substantial and rapid reductions in pain, enabling them to get back to their daily lives. Physicians are having very positive experiences with OGSIVEO, and as a consequence, there is a strong intent to prescribe it as a frontline treatment, and those that have prescribed it, importantly, are indicating that they expect to provide it more in the coming year. Following the successful OGSIVEO launch, we are preparing to bring mirdametinib for both adults and children with NF1-PN this year. NF1-PN is a chronic and highly debilitating disease. Patients face tremendous challenges as these tumors grow on peripheral nerve sheaths throughout the body, oftentimes becoming quite large and can compress vital organs as well. These patients suffer from severe pain, disfigurement, and loss of mobility, and in some cases, plexiform neurofibromas can also become malignant and fatal. These morbidities take a profound effect on these patients and their caregivers, both physically as well as on their mental health and quality of life. Mirdametinib has the potential to become the first FDA-approved treatment for adults with NF1-PN and the best-in-class treatment option for children. I'll speak later about our commercial preparations ahead of our anticipated approval. Let me spend a moment discussing where we are with OGSIVEO one year into our launch. First, I want to underscore the overwhelming toll that this disease has on patients and their families. Desmoid tumors are aggressive and invasive tumors that can arise in any part of the body. Their tendril-like growths can wrap around nearby tissue and compress vital organs and nerves. This can cause severe and chronic pain, loss of function, reduced mobility, disfigurement, and anxiety, all of which diminish a person's health and quality of life. Surgery, which had been used historically, is often a poor option for most desmoid tumor patients, given the very high degree of recurrence with surgery. For decades, patients were searching for an effective treatment and had only been offered off-label systemic therapies that were suboptimal and difficult to tolerate. In November of last year, in November of 2023, excuse me, OGSIVEO became the first and only FDA-approved therapy for adults with desmoid tumors. We are proud that the FDA approval of OGSIVEO has transformed the outlook for these patients. We also know that while OGSIVEO has become the systemic standard of care already, we believe that we have only scratched the surface on the number of patients who can benefit from our medicine. Our view of the overall opportunity is informed by the growing use of desmoid-specific ICD-10 diagnosis code, which was introduced in October 2023, just before our approval. In a 12-month period, 11,000 unique desmoid tumor patients have been identified through this new diagnosis code data based on having seen a physician throughout the course of this year. I'll remind everybody that this is an enriched pool of patients. You do not typically go get diagnosed for a desmoid tumor unless you have a symptom, and we expect that these patients, once you are being diagnosed with a desmoid tumor, have an over 90% likelihood of seeking treatment over the course of your life. So what we had anticipated before has only grown in terms of the number of patients we expect to help. Turning to our launch performance, this morning we announced $61.5 million in preliminary net product revenue for the fourth quarter, which represents a sequential 25% increase over the third quarter and brings our full year 2024 OGSIVEO net product revenue to $172 million. Based on the meaningful benefit patients are experiencing, OGSIVEO became the systemic standard of care for patients with desmoid tumors within months of approval. This strong and steady growth is driven by robust demand, both from new patient starts as well as existing patients who are continuing to experience significant benefits from OGSIVEO. The positive clinical experience that physicians have had has led to a strong preference for OGSIVEO as well as an intent to prescribe. While we're pleased with the strong start to our OGSIVEO launch, our belief is the opportunity for substantial growth exists going forward. Let me tell you why we're confident in what lies ahead. First, there is an addressable patient population that is meaningfully larger than we had initially estimated. That's the 11,000 patients with desmoid tumor ICD-10 claims I mentioned. As discussed, most patients will require treatment at some point, so we believe it's not a matter of if, but when they receive OGSIVEO. Second, we are very encouraged by the growing utilization of OGSIVEO. Physicians at Centers of Excellence were our earliest adopters, and OGSIVEO is firmly established as the systemic standard of care therapy in those centers. We expect to see continued growth at these academic centers. We're also seeing an increase in prescribing among community physicians, where we know a significant number of patients are getting treated. In fact, our market research shows that the majority of physicians expect to increase their use of OGSIVEO in the coming year, and 90% of prescribers are likely to use OGSIVEO now as a frontline treatment. While starting new patients on treatment is important, it's just as important that they are able to continue benefiting from therapy over time. Late last year, we presented long-term data from our phase III DeFi trial, which were highly supportive of the benefits of OGSIVEO when used for extended durations. These data showed that patients who were on therapy for a median of three years achieved further reductions in tumor size, an increased objective response rate, and sustained symptomatic improvements with prolonged treatment. This is measuring between year two and year three, so the continued benefit was felt by these patients over time. There were also no new safety signals that emerged with longer-term dosing. Third, evolving treatment dynamics further underpin our confidence in the opportunity. We are seeing physicians increasingly aligning their approach to care with the updated guidelines, which now favor systemic therapy over surgery for patients who require active treatment. Our survey work has also shown a recent shift towards initiating treatment based on symptoms rather than radiographic criteria. What that means for us is that with OGSIVEO 's broad label, which covers treatment based on either symptomatic or radiographic progression, we expect that more adult patients will become candidates for OGSIVEO earlier in the course of these treatments. We are working with urgency to bring OGSIVEO to patients outside of the United States this year. Our marketing authorization application is under review, and a decision from the European Commission is expected mid-year. Upon EMA approval, our EU launch will begin in Germany and then expand to other countries. We have the infrastructure in place and are well-positioned for a successful launch in Europe, given the high unmet need, the absence of an approved treatment for these patients. In addition, key opinion leaders and academic centers across Europe already have experience with OGSIVEO through our DeFi trial, as well as through our compassionate use program, which currently has more than 250 active patients. In Japan, we've had several successful discussions with the PMDA and expect to initiate a bridging study in Japanese patients this year, which we expect will support our NDA filing. We have also early access programs in place in France and Italy, as well as a newly active named patient program, all of which will help us provide OGSIVEO to more patients on a global basis. Moving now to mirdametinib. NF1-PN is a lifelong and highly debilitating disease that affects both children and adults. Plexiform neurofibromas can have periods of rapid growth. They can cause severe pain, compression of internal organs, disfigurement, and functional impairment, all of which significantly impacts the lives of patients and those who care for them. Plexiform neurofibromas can also become malignant and have fatal consequences, further driving the urgency to intervene. As with OGSIVEO for desmoid tumors, we again have the opportunity to serve a large patient population where approved therapies are either unavailable or unsatisfactory. There are approximately 100,000 people in the United States living with NF1, of whom 40,000 are estimated to have plexiform neurofibromas. Of these, 75% are adults, and those adults currently do not have an FDA-approved treatment. Surgery is often difficult for these patients due to the infiltrative growth of these plexiform neurofibromas along nerves, making total resection nearly impossible in most cases. Our market research suggests a highly fragmented treatment landscape with significant use of off-label therapies, even in pediatric patients for whom there is one approved medicine. There is a clear and substantial opportunity for us to address the needs of these patients. We believe mirdametinib has the potential to become a first-in-class therapy for adults with NF1-PN and a best-in-class option for pediatric patients. Positive results from our pivotal ReNeu trial show significant reductions in the size of plexiform neurofibroma tumors, robust objective response rates confirmed by blinded independent central review, and deep responses. Both adults and children experience early and sustained improvements in health-related quality of life over the course of treatment with mirdametinib, including clinically significant reductions in pain. We're also very pleased with the safety data emerging from the ReNeu trial. I'll touch on this more later, but physicians view mirdametinib's safety profile as differentiated due to low rates of Grade 3-related adverse events and low discontinuation rates. We believe this profile supports the potential for extended treatment durations, which is important in a lifelong disease like NF1-PN. On top of this, mirdametinib has a built-in drug holiday every three weeks and could further support tolerability in the real-world setting, and our oral tablet that dissolves easily in water finally provides an option for children and adults who have difficulty swallowing. We think on any of the dimensions that matter for patients in this disease, whether it's efficacy, safety, tolerability, convenience, we have the medicine for these patients. We've conducted multiple surveys to understand physician perceptions of mirdametinib's clinical profile and the role it can play in the treatment of patients with NF1-PN, and here's their feedback. First, the vast majority of physicians believe that there is still a substantial unmet need in both adult and pediatric patients, and this is despite the approved treatment option for children for the last three years. Second, mirdametinib's clinical efficacy and safety data are favorably differentiated from data in pediatric patients included in the FDA-approved labeling of selumetinib. While there have been no head-to-head studies evaluating mirdametinib and selumetinib, and any cross-trial comparisons must be done with caution, our survey revealed that a significant proportion of physicians found mirdametinib more compelling on both efficacy and safety metrics. What's most encouraging to us is that 90% of physicians indicated that they are likely to prescribe mirdametinib and that it will become a standard part of their treatment for patients with NF1-PN within 12 months. As you look across all of the metrics on this slide, whether it's the high unmet need, the differentiated profile, or the likelihood to prescribe, you can see a substantial enthusiasm from physicians to prescribe mirdametinib once approved. With the benefit of our successful OGSIVEO launch this past year, we are well-positioned to bring mirdametinib to patients with NF1-PN. We've chosen the brand name GOMEKLI, and in anticipation of approval, we've hired 35 field representatives who have an average of 20 years of experience in oncology, rare disease, and neurology. We were able to hire from a very high-quality team for mirdametinib, which we focused on the approximately 70 NF clinical network centers across the United States to start, but we'll quickly turn to other academic and community centers to drive adoption there as well. We'll also offer robust patient support services through our existing SpringWorks Care Connections program to help patients and caregivers get started and stay on track with mirdametinib. Our team is ready to execute another successful launch, now with mirdametinib, upon potential FDA approval. 2025 is set up to be another transformative year for SpringWorks. With the potential launch of our second medicine, our expansion to serve patients with these diseases globally, we are energized by the opportunity to continue delivering on the commitments we have made to the patient communities that we are dedicated to serving. Beyond OGSIVEO and mirdametinib, we have a diversified portfolio of targeted therapies at various stages of development. We believe that nirogacestat and mirdametinib have the potential to benefit oncology patients in other indications where significant unmet needs remain. As you can see from our pipeline, we have several monotherapy and combination therapies programs in flight. For nirogacestat, a phase II study is ongoing in patients with ovarian granulosa cell tumors. These tumors account for approximately 5% of all ovarian cancers, and there are no FDA-approved treatments for this patient population. We also have several BCMA collaborations in flight evaluating nirogacestat as a combination therapy in patients with multiple myeloma. For mirdametinib, one program I'll highlight is a monotherapy trial in pediatric and young adults with low-grade glioma. Positive data from the phase I portion of this study were reported by our collaborators at St. Jude at the end of 2024. Investigators reported responses in approximately 80% of patients receiving mirdametinib across a variety of MAPK pathway aberrations. The phase II portion of the study is ongoing, and we look forward to sharing more as the study progresses. Brimarafenib, a next-generation RAF dimer inhibitor that is being developed by MapKure, our joint venture with BeiGene, has also continued to advance. Monotherapy and combination therapy studies are underway, including a phase I-B trial, brimarafenib, Amgen's EGFR antibody, panitumumab, in colorectal and pancreatic cancer patients with MAPK pathway mutations. We've also made progress with our TEAD inhibitor, SW-682, and are enrolling patients in our phase I trial in patients with Hippo-mutant solid tumors. In our preclinical pipeline, we announced this morning that we signed an agreement with Rappta Therapeutics to in-license a molecule we have designated as SW-3431. This is a first-in-class small molecule activator of PP2A complexes that we believe has great promise for biomarker-defined subsets of patients with uterine cancer. We've got several important milestones to look forward to in 2025. As I've said, our PDUFA date for mirdametinib in NF1-PN is next month. We also expect a decision from the European Commission on both our OGSIVEO and mirdametinib applications in 2025. Mirdametinib has been granted rare pediatric disease designation by the FDA, which provides us the opportunity to receive a priority review voucher following approval. Simultaneously, we are pursuing the expansion opportunities I just mentioned for nirogacestat, and we expect initial data from our phase II study in ovarian granulosa cell tumors in the first half of this year. In our emerging pipeline, we expect additional data to be presented by MapKure from the brimarafenib monotherapy trial in the second half of 2025. And in parallel, with continuing enrollment of patients in our phase I study of SW-682, we expect to file an IND by the end of the year for SW-3431 and to be in the clinic next year with this new program. Now, I've spent most of my time today discussing the strong start to our OGSIVEO launch in the U.S. and the large opportunity we have for mirdametinib in patients with NF1-PN following our potential FDA approval next month. But our confidence and enthusiasm for our continued growth are driven by factors beyond just these two efforts. First, I'll highlight our opportunity to expand outside the United States. Desmoid tumors and NF1-PN are sizable markets in the U.S., and when we add the ability to serve the significant number of global patients who are living with these debilitating tumors, we are very excited about the possibilities ahead for these patient groups. Second is the excitement we have for our overall pipeline. Our late and early stage programs across a variety of indications provide the potential for us to develop important therapeutic options for patients who are currently underserved. And third, we believe that our strong balance sheet will enable us to execute on our base business without the need for more capital and puts us in a very favorable position. As we've highlighted, our expectation is to be profitable in the first half of 2026. Before I conclude my presentation, I'd like to once again thank the patients and families whose courage and resilience inspires our work, the investigators working on all of our clinical studies, and our team of SpringWorks for their dedication to our mission, and thank you once again, Anupam and the JP Morgan team for the opportunity to present today. Thanks, Saqib. You want to introduce who else is on stage here? Yeah. So joining us on stage alongside Anupam is our Chief Operating Officer, Dr. Badreddin Edris. He doesn't need an introduction. Everybody knows. You just asked me to introduce. Just want to remind folks three ways to ask a question. You can raise your hand. You can put it in the portal, and I'll ask it on your behalf, or you can email me. So, Saqib, just want to talk a little bit about what you saw for OGSIVEO and 4Q in terms of what were you seeing in terms of prescriber adds, repeat prescribers, patient uptake, and any seasonality that we should be considering in 4Q? Yeah. No, thanks for the question, Anupam. And I'd say that 4Q, I think, was a very strong quarter for us, and we did see an increase in, you know, we saw steady patient adds over the course of the quarter, so an increase in patients quarter on quarter. We saw it from repeat prescribers as well as new prescribers. We saw it in centers of excellence, so we have greater depth within those centers of excellence as well as in the community. I think there are a couple of things that I would highlight, though, and that's some of the information that I said in the presentation. From the group of prescribers that we have, over 60% say they expect to prescribe it more next year. That's not because they expect to see an increase in the number of diagnosed patients walk in. It's they expect to use it more within their patient population. I'd say that, obviously, we highlighted the ICD-10 claims now, which were 10,000 before, now 11,000. The depth of this patient population is, I think, really meaningful for us to kind of highlight, particularly when you combine that with the fact that over 90% of patients, once diagnosed, will get a treatment. Now you're moving towards more systemic treatment, and now we're moving even earlier in the place of that systemic treatment, looking at symptoms rather than just radiographic imaging. I think all of that bodes very well. To your specific question, we did see a little bit of seasonality, which, you know, now it's our first full year on the market when there's a Thanksgiving Christmas holiday. We did see some of that over the course of the quarter, but notwithstanding that, obviously, very pleased with the new patient adds. You've given ICD-10 code updates the last couple of quarters, right? It seems to be going up, right? How do we think about that trend? Yeah, I think it's, well, I'd say that a couple of things I'd highlight about these ICD-10 numbers. There, at the end of the day, I'm using that here as a proxy for the overall opportunity that we've got in terms of the number of patients. Functionally, we use it as a trigger for our commercial team to go and serve those patients and get to those physicians. So the existence of these codes are actually operationally very meaningful. But my sense is your question is about it as a marker for the size of the opportunity. In the past, we had talked about the number of patients who are currently on treatment or seeking treatment is about 5,500-7,000. We are already seeing about 11,000 people now with an ICD-10 claim. We've talked about how that is, I think, is a bit of a, you know, a sample that has got some bias in it because the likelihood to treat for that group becomes much higher. Now, we also believe that that is undercalling the opportunity. It typically takes two or three years before a new ICD-10 claim, a new ICD-10 code to be fully adopted for all claims data, and I think that's why we're seeing these numbers creep up over time because it is a bit of an undercall. Second, we are still getting kind of a meaningful minority of claims still on the old claims data, which means that, again, that 11,000 is an undercall of the size of the aggregate opportunity. Question from the audience? If you could raise your hand. Okay. Maybe you could talk a little bit about how you think about OGSIVEO and Europe. You mentioned Germany, obviously, first launch country, but maybe the cadence of adding on the big four countries plus the U.K. And then also, what is this infrastructure size in Europe relative to the U.S.? I think from an infrastructure perspective, you know, we are building it out sequentially, right? We have started in Germany. We've got people on the ground from both a medical and commercial perspective. In Germany, that is where we will begin, and we've got, you know, less than, you know, 10 people. From a sales perspective, we have the benefit of a little bit more both concentration of patients within centers of excellence and an awareness of the medicine, given that half of our sites from our phase III study were in Europe. So I think awareness is very high. I think the opportunity then, Germany, France, Italy, you know, I think we'll be adding on sequentially as we get beyond negotiations with each of those systems as it relates to price and all of the other elements that go towards the launch. So you're going to be staggering the adding of the sales force based on country reimbursement timelines? Exactly. Yeah. Okay. Questions from the audience? Maybe just talk about the push-pull levers on the path to profitability in the first half of 2026. Well, I think, you know, in terms of what's assumed within there, I'd say that are some pretty conservative assumptions on the mirdametinib launch on continued, certainly continued growth in OGSIVEO. We've given you all the reasons why we expect to see continued growth in OGSIVEO from a revenue perspective, but that factors in all of our assumptions around the cost for a second launch as well as what we're doing in our pipeline. So when we give you a statement about the first half of 2026, that's a fully loaded number. It's not cash flow positive in 2026. It's net income positive by 2026. Questions from the audience? Maybe switching gears a little bit to mirdametinib. When you think about relative to the OGSIVEO launch, what are the similarities and differences that you would point out? Yeah, no, I think it's a great question, and I think you've got to think about this in segments here. We believe, and we've said this based on the clinical experience of patients, but whether it's on the efficacy, safety, tolerability, or convenience, we will have a best-in-class medicine for children and a first-in-class medicine for adults. Now, those are two distinct markets because there is already one approved treatment in the United States for children. That is Alexion and AstraZeneca's Koselugo, and we believe, obviously, that there is an opportunity there. How we market the differentiated profile, which we've shown you the survey expectations, but then when the rubber meets the road, when you've got physicians who are making a prescribed decision, is going to be one set of activities. In adults, there is nothing approved. The adults, as we've shown, as I showed you on the market size, it's 3x the number of children in the United States alone and a proportionate number outside the United States. And that is an opportunity for us into a greenfield market, much more akin to what we did with OGSIVEO. You have to let people know that this is now available for them for the first time on label, and we think the opportunity is quite significant. Questions from the audience? You keep asking. It's not coming. I want to give people a chance. I guess, what is the street missing about mirdametinib, right, that you think is because it's not getting a ton of value at the current moment? Sure. Sure. Listen, I think ultimately, you know, and we can forgive people for being shortsighted, and you know, you look at what is approved, and the fixation on the quarter on quarter, I think, is natural and understandable. I think what is happening, and you know, not saying what anybody's missing or not, but in mirdametinib, probably akin to what it was for OGSIVEO, is that pre-approval, people don't, some people don't do the full work, and post-approval, then you see that you've actually got something here to sell. You've got patients that are out there who are going to benefit from it, and then those calculations come in. Now, I do think that in this case, that you've got some meaningful proxies out there. You've got one competitor with a drug that is still not the standard of care three years later, selling just to one quarter of the market, already doing about $500 million run rate. So if that is the case and three quarters of the market is still there and we still think we've got a chance to be best in class in the children, I think that is what's being missed, the aggregate size of the opportunity and the number of patients we can benefit in the U.S. and outside the U.S. But how do you see the uptake of mirdametinib in peds versus adult patients, right? You will be first in adults, but you also have a competitor in peds and the size differences. Well, on the one hand, for peds, I would say the difference is that it is a very organized market. Certainly, you know, all the work done by the Children's Tumor Foundation, the NF Consortium, you've got 70 centers of excellence in the United States, and it is a very organized group, oftentimes because it's the parents who are making sure that these children get treated, and so what we can say is comfortably that that market even now is highly unpenetrated and quite fragmented, so there is a meaningful opportunity there because you've got patients who are organized looking for a treatment, and there is less there. The larger number of adults aren't as well organized, and that is, you know, kind of the opportunity for us is to corral with us with a neuro-oncologist or the other treating physicians is to get patients back in and to let them know that there is something for them that is actually meaningful that they can stay on treatment for. Again, the analogies for what we did with OGSIVEO is actually pretty clear. Hang on. Any questions from the audience? No? Okay, go ahead. I'm not going to ask no more because nobody would be asking. You mentioned the deal that you did. Yes. Talk to us about you've got this pipeline, just looking at BCMA, you've got OGSIVEO in different indication, you've got this new asset. Like, how do you think about BD right now relative to how, you know, you're trying to achieve profitability and you've got a pipeline already? So all of our views on our profitability have not changed with, you know, with this in license of this preclinical asset that we're going to be exploring in the clinic. I do think that, you know, the lion's share of focus is going to be on our two lead programs, which are, you know, going to one launch and then three launches coming up, but then there is a bit of a gap because you look at most of our portfolios, kind of phase I going into phase II, and so as you look at what's coming in, there is a bit of a gap to approval. There's plenty of data that's going to be coming from these programs, so I think the BD mark, the threshold for BD is high. I think we believe everything we have put our resources into is focused on making meaningful benefit to a large group of patients, and I think that becomes a standard. Anything that diverts from that, I think, risks both fragmentation of focus as well as fragmentation of capital. So any large-scale BD is not factored into our view of profitability, but I'd say that that would have to pay for itself independently. Yeah, go ahead. Oh, welcome. I really do have one. Thank you. Do you think you can expand into any other sarcomas beyond just the desmoid? We're exploring that right now. We're exploring that. The question for those who didn't hear online was, is there a possibility to expand beyond sarcomas for our gamma secretase inhibitor? And we are certainly evaluating that. Yeah. That's it. Any other questions from the audience? I was asking to get one. The ovarian granulosa, maybe you can expand on that opportunity and how you're thinking about data there. Sure. So that's a fully enrolled phase II trial that we'll be reporting data on this half. Ovarian granulosa cell tumors represent about 5% of ovarian cancers that are driven by activating mutations in a transcription factor called FOXL2. And so the rationale behind taking OGSIVEO into this phase II trial is the reliance of that signaling cascade on the notch pathway. And so that really formed the basis. This is a disease with no approved therapies where patients really face a whole host of off-label options such as platinum-based chemotherapies, anti-VEGFs, etc. And so we enroll the patient population that fundamentally has seen all of those therapies, has been on anti-hormonal, so they're quite far advanced. And so really any clinical benefit that these patients can derive from an oral therapy is something that I think physicians would be interested in using. Certainly, this is a situation where all of the usage is driven off of guidelines. And so with OGSIVEO already approved in desmoid tumors, we could potentially have that flexibility upon publication of the data. Any final questions? All right. Thank you all. Thanks for coming.